Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma

Figure 4 Comparing the survival of camrelizumab plus apatinib and hepatic artery infusion chemotherapy alone and camrelizumab plus apatinib and hepatic artery infusion chemotherapy combined with microwave ablation treatment for patients with advanced hepatocellular carcinoma. A-D: Kaplan-Meier curves for the overall survival (OS) (A), progression-free survival (PFS) (B), intrahepatic PFS (IPFS) (C) and extrahepatic PFS (EPFS) (D) of patients with advanced hepatocellular carcinoma before propensity score matching (PSM); E-H: Kaplan-Meier curves for the OS (E), PFS (F), IPFS (G) and RPFS (H) of patients with advanced hepatocellular carcinoma after PSM. T-M: Camrelizumab plus apatinib and hepatic artery infusion chemotherapy combined with MWA; T-A: Camrelizumab plus apatinib and hepatic artery infusion chemotherapy alone; OS: Overall survival; PFS: Progression-free survival; IPFS: Intrahepatic progression-free survival; EPFS: Extrahepatic progression-free survival; HR: Hazard ratio; CI: Confidence interval.